Surface Oncology to Participate in Citi's 2022 Virtual Immuno-Oncology Summit
Surface Oncology (Nasdaq: SURF) announced its participation in a fireside chat at Citi's 2022 Virtual Immuno-Oncology Summit on February 16, 2022, at 8 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surface Oncology (Nasdaq: SURF) announced its participation in a fireside chat at Citi's 2022 Virtual Immuno-Oncology Summit on February 16, 2022, at 8 a.m. ET. The event will provide insights into the company's next-generation immunotherapies targeting the tumor microenvironment. Surface's portfolio includes clinical programs focusing on CD39 and IL-27, along with partnerships with Novartis and GlaxoSmithKline. A live audio stream and archived webcast will be available on the company's website.
Details
News Market Reaction – SURF
The recorded move for SURF in the trading session of this news was -1.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that company management will participate in a fireside chat during Citi's 2022 Virtual Immuno-Oncology Summit.
The presentation begins at 8 a.m. ET on Wednesday, February 16, 2022. The live audio and subsequent archived webcast of the fireside chat will be accessible from the Events page of the company’s website.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562; IND filed). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.